Valuation: Exactus Inc

Market Cap 5L 5L 4L 4L 7L 4.95Cr 7L 49.5L 19.43L 2.47Cr 19.49L 19.06L 8.27Cr P/E 2022
-0.11x
P/E 2023 -0.31x
Enterprise Value 2.2Cr 1.92Cr 1.78Cr 1.64Cr 3.09Cr 210.48Cr 3.14Cr 21Cr 8.25Cr 104.78Cr 8.28Cr 8.1Cr 351.36Cr EV / Sales 2022
11.6x
EV / Sales 2023 10.1x
Free-Float
-
Yield 2022 *
-
Yield 2023 -
18/11 Panacea Life Sciences Holdings and Benivita Inc. Launch Benivita PLSH CI
06/24/06 Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
01/24/01 Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
01/24/01 Panacea Life Sciences Holdings, Inc. Auditor Raises 'Going Concern' Doubt CI
15/23/15 Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
05/23/05 Panacea Life Sciences Holdings, Inc. completed the acquisition of N7 Enterprises, Inc. CI
02/23/02 Panacea Life Sciences Holdings, Inc. entered into an Asset Purchase Agreement to acquire PÜR LIFE Medical, Inc. CI
30/23/30 Panacea Life Sciences Holdings, Inc. completed the acquisition of Nitro Kava & Kratom from Gary Wilder, Lizard Juice, LLC, N7 Enterprises, Inc. and New Age Distribution Corp. for $7.8 million. CI
15/23/15 Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
02/23/02 Panacea Life Sciences Holdings, Inc. entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million. CI
10/23/10 Panacea Life Sciences Holdings, Inc. agreed to acquire Nitro Kava & Kratom. CI
10/23/10 Panacea Life Sciences Holdings, Inc. entered into agreements acquire 8 Retail Locations in the Tampa, Florida. CI
15/23/15 Panacea Life Sciences Holdings, Inc. Distribution Division Signs Exclusive Distribution Agreement with QR Joy to Distribute U.S. Top Fume Disposable Vape Devices in the U.K CI
Change 5-day change 1-year change 3-year change Capi.($)
-2.44%-6.49%+45.62%+149.31% 1,02400Cr
-1.53%-5.37%+47.14%+47.48% 62TCr
-2.05%-4.39%+24.57%+64.80% 44TCr
+0.24%-1.69%+38.82%+32.61% 35TCr
-1.41%-3.03%+31.76%+39.93% 30TCr
-8.65%-10.69%+3.36%+5.60% 26TCr
-7.65%-7.72%-3.74%-43.86% 21TCr
-1.51%+0.94%+25.78%+64.62% 21TCr
-0.24%-0.97%+12.88%+71.14% 16TCr
Average -2.17%-1.35%+25.13%+47.96% 39.71TCr
Weighted average by Cap. -2.17%-2.17%+32.82%+70.38%

Financials

2022 2023
Net sales 16.27L 14.14L 13.16L 12.09L 22.82L 16Cr 23.18L 1.55Cr 60.9L 7.73Cr 61.1L 59.76L 26Cr 23.85L 20.73L 19.3L 17.72L 33.46L 23Cr 33.98L 2.27Cr 89.27L 11Cr 89.57L 87.6L 38Cr
Net income -91.43L -79.48L -73.98L -67.92L -1.28Cr -87Cr -1.3Cr -8.72Cr -3.42Cr -43Cr -3.43Cr -3.36Cr -145.69Cr -80.15L -69.68L -64.85L -59.54L -1.12Cr -77Cr -1.14Cr -7.64Cr -3Cr -38Cr -3.01Cr -2.94Cr -127.73Cr
Net Debt 1.79Cr 1.55Cr 1.44Cr 1.33Cr 2.5Cr 170.43Cr 2.54Cr 17Cr 6.68Cr 85Cr 6.71Cr 6.56Cr 284.51Cr 2.15Cr 1.87Cr 1.74Cr 1.6Cr 3.02Cr 205.52Cr 3.07Cr 21Cr 8.06Cr 102.32Cr 8.09Cr 7.91Cr 343.09Cr
Logo Exactus Inc
Exactus, Inc. is a healthcare company. The Company is focused on manufacturing hemp derived Cannabidiol (CBD) products. It sells its CBD products through its Exactus brand and white label products to third-party resellers. It is also engaged in producing industrial hemp from farms in Oregon. Its products product line includes hemp flower, pre-rolled hemp flower, topicals, tinctures and concentrates. It also offers point-of-care diagnostic tools to analyze biometric markers in a drop of blood. Its FibriLyzer product provides solution to assess the fibrinolytic status of patients in a broad range of applications, including surgery, trauma, orthopedics, heart, stroke and chronic coronary disease management. Its MatriLyzer product detects the initial occurrence or the recurrence of cancer during routine office visits.
Employees
-